オピオイド誘発性便秘症(OIC)治療薬の世界市場:パイプラインレビュー(2019上半期)

【英語タイトル】Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2019

Global Markets Directが出版した調査資料(DATA906A281)・商品コード:DATA906A281
・発行会社(調査会社):Global Markets Direct
・発行日:2019年1月31日
・ページ数:51
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprisewide(複数事業所内共有可)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Opioid-Induced Constipation (OIC) – Pipeline Review, H1 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Constipation (OIC) – Pipeline Review, H1 2019, provides an overview of the Opioid-Induced Constipation (OIC) (Toxicology) pipeline landscape.

Opioids are effective pain relievers, but often have the side effect of constipation. These medicines affect the gastrointestinal tract in a variety of ways. Opioids increase the amount of time it takes stool to move through the gastric system. They increase non-propulsive contractions in the middle of the small intestine (jejunum) and decrease longitudinal propulsive peristalsis – motions critical to moving food through the intestines. This results in food that fails to travel through the digestive tract. Opioids are also able to partially paralyze the stomach (gastroparesis) so that food remains in the digestive organ for a longer period of time. Additionally opioids reduce digestive secretions and decrease the urge to defecate. Symptoms of OIC include feeling and being sick, tiredness and lethargy, appetite loss, feeling depressed.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Opioid-Induced Constipation (OIC) – Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opioid-Induced Constipation (OIC) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Constipation (OIC) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Phase II stages are 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Opioid-Induced Constipation (OIC) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC) (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Opioid-Induced Constipation (OIC) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Opioid-Induced Constipation (OIC) (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Opioid-Induced Constipation (OIC) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Opioid-Induced Constipation (OIC) (Toxicology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Opioid-Induced Constipation (OIC) (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Opioid-Induced Constipation (OIC) – Overview
Opioid-Induced Constipation (OIC) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Opioid-Induced Constipation (OIC) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Opioid-Induced Constipation (OIC) – Companies Involved in Therapeutics Development
MallInckrodt Plc
Shionogi & Co Ltd
Synergy Pharmaceuticals Inc
Opioid-Induced Constipation (OIC) – Drug Profiles
dolcanatide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lubiprostone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naldemedine tosylate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone hydrochloride PR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Opioid-Induced Constipation (OIC) – Dormant Projects
Opioid-Induced Constipation (OIC) – Discontinued Products
Opioid-Induced Constipation (OIC) – Product Development Milestones
Featured News & Press Releases
Dec 18, 2018: Shionogi receives positive opinion for Rizmoic in latest announcement from the Committee for Medicinal Products for Human Use (CHMP)
Dec 13, 2018: Rizmoic (naldemedine) received a positive opinion for the treatment of opioid-induced constipation
Sep 04, 2018: Shionogi announces upcoming presentations from Symproic (naldemedine) studies at PAINWeek 2018 Annual Conference
Jul 09, 2018: Shionogi Regains Full Rights to Symproic (naldemedine) in the US
Mar 06, 2018: Fifty-Two Week Safety Study on Symproic (naldemedine) for Opioid-induced Constipation (OIC) in Adults with Chronic Non-cancer Pain Published in PAIN
Oct 12, 2017: Shionogi and Purdue Pharma Announce U.S. Availability of Symproic (naldemedine) for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain
Sep 06, 2017: Shionogi and Purdue Pharma to Present Data from Naldemedine Studies at PAINWeek 2017 Annual Conference
Jun 07, 2017: Opioid-Induced Constipation therapeutic agent ‘Symproic (naldemedine) Tablets 0.2mg’ launched in Japan
Mar 30, 2017: Symproic (naldemedine) Approved for the Treatment of Opioid-Induced Constipation in Japan
Mar 24, 2017: EMA Accepts MAA Submission of Shionogi’s Naldemedine for the Treatment of Opioid-Induced Constipation
Mar 23, 2017: FDA Approves Symproic (naldemedine) Once-Daily Tablets C-II for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain
Dec 19, 2016: Shionogi and Purdue Pharma Establish Alliance for Joint U.S. Commercialization of Naldemedine
Sep 07, 2016: Naldemedine Phase III Study Demonstrates Long-Term Safety And Efficacy For The Treatment Of Opioid-Induced Constipation
Jun 06, 2016: Shionogi Announces Acceptance Of New Drug Application In The U.S. For Naldemedine For The Treatment Of Opioid-Induced Constipation
May 23, 2016: Two Naldemedine Phase III Studies Show Consistent Improvement Of Opioid-Induced Constipation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Opioid-Induced Constipation (OIC) - Pipeline by MallInckrodt Plc, H1 2019
Opioid-Induced Constipation (OIC) - Pipeline by Shionogi & Co Ltd, H1 2019
Opioid-Induced Constipation (OIC) - Pipeline by Synergy Pharmaceuticals Inc, H1 2019
Opioid-Induced Constipation (OIC) - Dormant Projects, H1 2019
Opioid-Induced Constipation (OIC) - Discontinued Products, H1 2019

List of Figures
Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Targets, H1 2019
Number of Products by Stage and Targets, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

【掲載企業】

MallInckrodt Plc、Shionogi & Co Ltd、Synergy Pharmaceuticals Inc

★調査レポート[オピオイド誘発性便秘症(OIC)治療薬の世界市場:パイプラインレビュー(2019上半期)] (コード:DATA906A281)販売に関する免責事項を必ずご確認ください。
★調査レポート[オピオイド誘発性便秘症(OIC)治療薬の世界市場:パイプラインレビュー(2019上半期)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆